Validation of a Regional Citrate Anticoagulation Protocol in Critically Ill Patients on Continuous Renal Replacement Therapy
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
43 participants
Nov 24, 2024
INTERVENTIONAL
Conditions
Summary
The objective of this study is to evaluate the effectiveness of a modified continuous renal replacement therapy (CRRT) protocol in maintaining electrolyte balance in adult patients with acute kidney injury (AKI) admitted to the intensive care unit (ICU). The study assesses whether the use of continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement under citrate anticoagulation reduces electrolyte losses and the need for electrolyte supplementation compared with standard dialytic CRRT. Participants receiving standard CRRT will be compared with those treated with the modified protocol. The duration of participation corresponds to the period during which CRRT is required. Data collection will cease once CRRT is discontinued.
Eligibility
Inclusion Criteria3
- Age ≥18 years
- Admission to the intensive care unit (ICU)
- Diagnosis of acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT)
Exclusion Criteria3
- Known allergy or intolerance to citrate
- Contraindications to citrate anticoagulation (e.g., severe liver failure or severe metabolic disorders affecting citrate metabolism)
- Pregnancy or breastfeeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Continuous renal replacement therapy (CRRT) using regional citrate anticoagulation. Treatment modalities include continuous venovenous hemodialysis (CVVHD) and continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement, depending on study group assignment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07514650